Allianz Asset Management GmbH Raises Stock Position in Solventum Corporation $SOLV

Key Points

• Allianz Asset Management GmbH increased its stake in Solventum Corporation by 330.7%, owning 77,509 shares valued at approximately $5.88 million.
• Solventum reported a quarterly earnings per share (EPS) of $1.69, surpassing analyst expectations by $0.24, with revenue rising by 3.8% year-over-year.
• Brokerage firms have shown positive sentiment towards Solventum, with recent ratings upgrades and target prices ranging from $77.00 to $103.00.

Allianz Asset Management GmbH boosted its position in Solventum Corporation (NYSE:SOLV - Free Report) by 330.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 77,509 shares of the company's stock after purchasing an additional 59,511 shares during the quarter. Allianz Asset Management GmbH's holdings in Solventum were worth $5,878,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Rossby Financial LCC purchased a new stake in shares of Solventum in the first quarter worth $25,000. Strengthening Families & Communities LLC increased its stake in Solventum by 376.8% in the 1st quarter. Strengthening Families & Communities LLC now owns 329 shares of the company's stock worth $25,000 after acquiring an additional 260 shares during the last quarter. Barrett & Company Inc. raised its holdings in shares of Solventum by 206.2% in the 2nd quarter. Barrett & Company Inc. now owns 398 shares of the company's stock valued at $30,000 after acquiring an additional 268 shares in the last quarter. Hara Capital LLC bought a new stake in shares of Solventum during the 1st quarter valued at about $38,000. Finally, Smartleaf Asset Management LLC grew its holdings in shares of Solventum by 193.4% during the first quarter. Smartleaf Asset Management LLC now owns 534 shares of the company's stock worth $40,000 after purchasing an additional 352 shares in the last quarter.

Solventum Price Performance

Shares of NYSE:SOLV opened at $72.73 on Thursday. The company has a quick ratio of 0.86, a current ratio of 1.22 and a debt-to-equity ratio of 2.14. The stock has a market cap of $12.61 billion, a PE ratio of 33.67, a PEG ratio of 2.97 and a beta of 0.50. The company's fifty day moving average is $72.64 and its 200 day moving average is $72.02. Solventum Corporation has a 52 week low of $60.70 and a 52 week high of $85.92.

Solventum (NYSE:SOLV - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $1.69 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.45 by $0.24. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The firm had revenue of $2.16 billion for the quarter, compared to analysts' expectations of $2.12 billion. During the same period last year, the firm earned $1.56 earnings per share. The company's revenue for the quarter was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Research analysts anticipate that Solventum Corporation will post 6.58 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on SOLV. Argus raised shares of Solventum from a "hold" rating to a "buy" rating and set a $90.00 target price on the stock in a research note on Tuesday, July 1st. UBS Group initiated coverage on shares of Solventum in a report on Wednesday, October 1st. They set a "neutral" rating and a $77.00 price objective for the company. Piper Sandler reiterated an "overweight" rating and issued a $94.00 target price (up from $87.00) on shares of Solventum in a research report on Friday, August 8th. Morgan Stanley upgraded Solventum from an "equal weight" rating to an "overweight" rating and raised their price target for the company from $80.00 to $103.00 in a research report on Tuesday, July 15th. Finally, Wells Fargo & Company upped their price objective on Solventum from $79.00 to $82.00 and gave the stock an "equal weight" rating in a report on Monday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Solventum presently has an average rating of "Hold" and an average price target of $84.89.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.